Fig. 2: Inhibition of VEGFR-3 by SAR131675 decreases the resiquimod-induced lupus nephritis.

A Serum creatinine levels, urine albumin/creatinine ratio, and anti-dsDNA antibody levels after SAR131675 treatment in the resiquimod-induced LN. B Gross finding of the spleen after SAR131675 treatment in the resiquimod-induced LN. The bar graph shows the spleen/body weight ratio (%). C Representative sections of kidneys from each experimental group of SAR131675 treatment in the resiquimod-induced LN were stained with Hematoxylin and Eosin (H&E) with magnification of 200× and 400×. Scale bar = 50 μm. The bar graph shows semi-quantitative scoring of kidney injury by H&E in each experimental group. D Representative sections of kidneys from each experimental group of SAR161675 treatment in the resiquimod-induced LN were immunofluorescence stained with glomerular immune complex IgM, IgG, and C3; Scale bar = 50 μm. The bar graph shows a mean fluorescence intensity in each experimental group. Statistical significance was determined using one-way ANOVA followed by Tukey’s post-hoc test. Data are expressed as mean ± SD. ****P < 0.0001 versus each group. Control, vehicle-treated group; SAR, SAR131675-treated group; Lupus, resiquimod-treated group; Lupus+SAR, resiquimod and concomitantly SAR131675-treated group. Anti-dsDNA antibody, anti-double-stranded DNA antibody, C3 complement component 3, DAPI 4’,6-diamidino-2-phenylindole, IgM immunoglobulin M, IgG immunoglobulin g, LN lupus nephritis.